Treace Medical Concepts, Inc. Announces Pricing of $100.0 Million Public Offering of Common Stock
All of the shares of common stock are being offered by Treace and there are no selling stockholders participating in the offering.
- All of the shares of common stock are being offered by Treace and there are no selling stockholders participating in the offering.
- In addition, Treace has granted the underwriters a 30-day option to purchase up to an additional 714,285 shares of common stock at the public offering price, less underwriting discounts and commissions.
- The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Treace, are expected to be approximately $100.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.
- The offering is expected to close February 10, 2023, subject to the satisfaction of customary closing conditions.